O. Sitbon (Le Kremlin-Bicêtre, France), C.D. Vizza (Rome, Italy), J. Lordan (Newcastle-Upon-Tyne, United Kingdom), R. Condliffe (Sheffield, United Kingdom)
Assessment of pulmonary hypertension in patients over 70
C. Valerio, B. Schreiber, C. Handler, C. Denton, J. Coghlan (London, United Kingdom)
|   |
Pulmonary hypertension in a district general hospital
Y.P. Lin, D. Davenport, N. Shrikrishna, A. Cole, H. Ranu (Chichester, United Kingdom)
| |
Pulmonary arterial hypertension prototype for national protocol and registry
M. Malekmohammad, F. Fahimi, B. Sharifkashani, M.R. Masjedi (Tehran, Islamic Republic Of Iran)
| |
Pulmonary hypertension: The experience of a large UK district general hospital
S. Clarke, G. Swarbrick, S. Baddeley, J. Chadwick, T. Saba (Blackpool, United Kingdom)
| |
Stability of a new formulation of intravenous epoprostenol sodium
O. Lambert, D. Bandilla (Allschwil, Switzerland)
| |
Pulmonary arterial hypertension: Long term effects of oral ambrisentan on clinical status, exercise capacity and haemodynamics
M. D‘Alto, E. Romeo, P. Argiento, A. Correra, B. Sarubbi, A. D‘Andrea, A. Caronna, M. Pignatiello, N. Grimaldi, R. Calabrò, M.G. Russo (Naples, Italy)
| |
Incidence of subdural hematoma in patients with pulmonary arterial hypertension (PAH) in two randomized controlled clinical trials
G. Simonneau, L.J. Hwang, S. Teal, N. Galie (Paris, France; Bologna, Italy)
| |
Long-term bosentan therapy improves exercise capacity and hemodynamics in sarcoidosis-associated pulmonary hypertension
D. Qua, V. Palmero, R. Sulica (New York, United States Of America)
| |
First long-term experience with intravenous treprostinil administered by the implantable infusion pump LenusPro. A single-center pilot study
R. Steringer-Mascherbauer, V. Eder, C. Huber, S. Wittrich, R. Fuegger, U. Fröschl, H.J. Nesser (Linz, Austria)
| |
An international survey of current pulmonary arterial hypertension (PAH) management
I. Preston, B. Hinzmann, N. Bawden, H. Tiede (Boston, United States Of America; Berlin, Giessen, Germany; London, United Kingdom)
| |
Comparison of the pharmacokinetic, pharmacodynamic, and safety profiles of three different formulations of intravenous epoprostenol sodium
L. Nicolas, M. Gutierrez, J. Dingemanse (Allschwil, Switzerland)
| |
Lack of relevant pharmacokinetic interactions between the new dual endothelin receptor antagonist macitentan and sildenafil in healthy subjects
P. Sidharta, P. van Giersbergen, M. Wolzt, J. Dingemanse (Allschwil, Switzerland; Vienna, Austria)
| |
EPITOME-2: Evaluation of a new formulation of epoprostenol sodium in pulmonary arterial hypertension patients switched from an originally approved formulation
O. Sitbon, M. Delcroix, E. Bergot, A. Boonstra, P. Escribano Subias, N. Galiè, J. Granton, D. Langleben, T. Pfister, J.C. Lemarié, G. Simonneau (Le Kremlin Bicêtre, Caen, Paris, France; Leuven, Belgium; Amsterdam, Netherlands; Madrid, Spain; Bologna, Italy; Toronto, Montreal, Canada; Allschwil, Switzerland)
| |
Outcomes from use of targeted therapy in pulmonary hypertension associated with sarcoidosis (PHAS)
J. Cannon, C. McCabe, J. Pepke-Zaba, K. Sheares (Cambridge, United Kingdom)
| |
Ambrisentan for therapy of portopulmonary hypertension (POPH): Update on safety and efficacy
R. Cartin-Ceba, K. Swanson, M. Krowka (Rochester, United States Of America)
| |
Lack of relevant pharmacokinetic and pharmacodynamic interactions between the new dual endothelin receptor antagonist macitentan and warfarin in healthy subjects
P. Sidharta, H. Dietrich, J. Dingemanse (Allschwil, Switzerland; Cologne, Germany)
| |
Absorption behavior of riociguat (BAY 63-2521): Bioavailability, food effects, and dose-proportionality
C. Becker, R. Frey, C. Hesse, S. Unger, M. Reber, W. Mueck (Wuppertal, Germany)
| |
Effect of ambrisentan, bosentan and macitentan on human hepatic uptake and efflux transporters
H. Gillies, I. Lepist, J. Hao, A. Ray (Foster City, United States Of America)
| |
Bosentan influence on catecholamines levels in patients with idiopathic arterial pulmonary hypertenson
E. Kobal, T. Martynyuk, O. Arkhipova, V. Masenko, S. Nakonechnikov, I. Chazova (Moscow, Russian Federation)
| |
Endothelin-1 downregulates BMP signaling in pulmonary artery smooth muscle cells
H. Maruyama, C. Dewachter, A. Belhaj, B. Rondelet, M. Remmelink, J.L. Vachiery, R. Naeije, L. Dewachter (Brussels, Belgium)
| |